Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone?
Alcántara
A G
AG
D058669:Adrenergic alpha-2 Receptor Antagonists; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D006212:Hallucinations / Q000139:chemically induced* / Q000378:metabolism; D006801:Humans; D010468:Perceptual Disorders / Q000139:chemically induced / Q000378:metabolism*; D051381:Rats; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism; D018967:Risperidone / Q000009:adverse effects*; D012702:Serotonin Antagonists / Q000009:adverse effects*
D058669:Adrenergic alpha-2 Receptor Antagonists; D014150:Antipsychotic Agents; D018341:Receptors, Adrenergic, alpha-2; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D018967:Risperidone